Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004082 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00004082: Completed Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Beth Israel Deaconess Medical Center.
NCT00004082 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that has completed, run by Beth Israel Deaconess Medical Center. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004082, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining docetaxel, carboplatin, and gemcitabine in treating patients who have previously untreated, newly diagnosed epithelial cancer.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG docetaxel
- DRUG gemcitabine hydrochloride
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT00004082 record still lists
NCT00004082 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which carboplatin is the first listed.
NCT00004082 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00004082 about?
NCT00004082 is a clinical study titled "Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combining docetaxel, carboplatin, and gemcitabine in treating patients...
What is the current status of trial NCT00004082?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-07. Estimated completion is 2010-12.
What conditions does trial NCT00004082 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer.
What interventions are being tested in trial NCT00004082?
The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00004082?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004082 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia